BSX

Business Context and Reporting Period

Company: Boston Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Boston Scientific is a global developer, manufacturer, and marketer of medical devices for interventional specialties, including cardiology, endoscopy, urology, and neuromodulation. The company focuses on less-invasive procedures. A primary growth driver in 2004 was the commercial success of the TAXUS® Express 2 drug-eluting coronary stent system, which accounted for approximately 38% of net sales. The company also expanded into the neuromodulation market through the acquisition of Advanced Bionics Corporation in June 2004.

Key Financial Metrics (2004)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 62% year-over-year, driven primarily by $2.14 billion in TAXUS stent sales (up from $198 million in 2003). U.S. sales grew 82%, while international sales grew 37%.
• Profitability: Gross margin expanded 4.6 percentage points to 77.0%, largely due to a favorable product mix shift toward higher-margin drug-eluting stents. This was partially offset by $57 million in inventory write-downs related to product recalls and shelf-life dating.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 49% to $1.74 billion due to increased marketing, headcount, and commissions for the TAXUS program, as well as a $110 million 401(k) plan enhancement and $90 million in stock option modification charges. R&D expenses increased 26% to $569 million.
• Acquisitions: The company invested significantly in strategic growth, including the $740 million acquisition of Advanced Bionics and $65 million in purchased R&D expenses.
• Debt Structure: Gross debt increased to $2.37 billion as the company issued $1.1 billion in senior notes to fund acquisitions and share repurchases, while simultaneously reducing commercial paper balances.

Guidance, Outlook, and Risks

• Market Outlook: Management expects the worldwide coronary stent market to exceed $5 billion in 2005, with drug-eluting stents representing approximately 87% of that market. The company anticipates continued growth in drug-eluting stent sales in 2005 due to full-year U.S. sales and increased adoption in Europe and Inter-Continental markets.
• Product Pipeline: The company plans to launch the next-generation TAXUS Liberté stent in Europe in 2005 and the U.S. in 2006. Launch in Japan is expected in late 2006 pending regulatory approval.
• Key Risks:
  • Competition: The coronary stent market is highly competitive. Johnson & Johnson's acquisition of Guidant Corporation may increase market volatility. New entrants are expected in the U.S. drug-eluting stent market in 2006.
  • Regulatory & Reimbursement: Delays in regulatory approvals (particularly in Japan) and changes in reimbursement policies could materially impact revenues. The company faces significant intellectual property litigation with competitors including Johnson & Johnson, Medtronic, and Medinol.
  • Product Liability: The company is substantially self-insured for product liability claims. While historical losses have not been material, unanticipated catastrophic losses could impact financial position.
  • Japan Market: Operating income in Japan is expected to decrease by approximately $70 million in 2005 due to pricing reductions and the lack of a drug-eluting stent launch.
• Unusual Items: In 2004, the company recorded net after-tax charges of $332 million ($0.39 per share), including provisions for legal exposures, 401(k) enhancements, and stock option modifications. The company also voluntarily recalled approximately 88,000 TAXUS Express 2 stents, resulting in a $43 million inventory write-down.

Investor Verification Checklist

• TAXUS Stent Adoption Rates: Verify the continued conversion rate of physicians from bare-metal to drug-eluting stents in the U.S. (estimated at 85% in 2004) and international markets.
• Japan Regulatory Status: Monitor the timeline for FDA/PMODA approval of the TAXUS stent in Japan, as delays could exacerbate market share loss to competitors.
• Intellectual Property Litigation: Track the outcomes of ongoing patent disputes with Johnson & Johnson, Medtronic, and Medinol, as adverse rulings could restrict sales or require royalty payments.
• Inventory Management: Assess the company's ability to manage inventory levels for the TAXUS platform to avoid future write-downs related to shelf-life or demand forecasting errors.
• Acquisition Integration: Evaluate the integration progress and revenue contribution of Advanced Bionics and other strategic alliances.
• Debt Maturities: Review the schedule for debt repayments, specifically the $500 million senior notes maturing in March 2005.